CD19 CAR-T后复发难治性非霍奇金淋巴瘤挽救性放疗的早期经验
该研究回顾性分析了14例CD19 CAR-T治疗后进展并接受挽救性放疗(SRT)的非霍奇金淋巴瘤患者,多数因CAR-T后首次复发(71%)且放疗部位为CAR-T前PET高代谢病灶(79%)。SRT后中位总生存期为10个月,局部复发患者缓解率达100%,且后续复发自由时间和总生存均优于晚期复发患者。部分患者桥接异基因移植后均存活无病。
要点
- SRT后中位OS为10个月,局部复发者缓解率100%。
- 局部复发者后续复发自由时间和OS优于晚期复发者。
- SRT可桥接异基因移植,部分患者达持续缓解。
核心结论
- SRT是CAR-T后进展的可行挽救策略,局部复发患者获益更明显。
研究设计与样本
- 回顾性分析14例CD19 CAR-T治疗后进展并接受SRT的非霍奇金淋巴瘤患者。
主要发现
- SRT后中位OS为10个月。
- 6例局部复发患者SRT后均缓解(3例完全缓解,3例部分缓解)。
- 3例桥接异基因移植,分析时均存活且无病。
关键数值与推荐
- 71%的患者因CAR-T后首次复发接受SRT。
- 79%的放疗部位为CAR-T前PET高代谢病灶。
临床怎么用
- SRT可与新药或移植整合,用于CAR-T后局部复发患者以争取持久缓解。
局限性
- 样本量小(14例),为回顾性研究,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.
引用
- Imber BS, Sadelain M, DeSelm C, et al. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. Br J Haematol. 2020. PMID: 32135029. doi:10.1111/bjh.16541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。